Author

M. F. Nold

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Interleukin-37 does not confer protection against stone formation or kidney injury at the peak of disease in a murine calcium oxalate model

Calcium oxalate (CaOx) stones are the most prevalent form of nephrolithiasis in adults. While murine models of CaOx stone disease are established, many lack translational features for therapeutic evaluation, including in vivo assessment of kidney function and molecular profiling of renal inflammation. We refined the gl...

N. Bhatt, Theresa T. Nguyen, I. Rudloff et al. · Urolithiasis · 0 citations

Open access Sep 2026

Model‐Informed Dose Optimization of Anakinra in Preterm Neonates Implications for Safe and Effective Dosing

The developed population PK model for anakinra delivers the first critical understanding of small protein PK in premature neonates, establishing a foundation for evidence‐based dosing strategies to guide future prospective clinical trials.

Jia Li, D. Metz, Elys A. Green et al. · Clinical pharmacology and th... · 0 citations

Review Open access Jul 2026

Clinical Pharmacokinetics and Pharmacodynamics of the IL-1 Receptor Antagonist Anakinra: A Systematic Review

Current available data are insufficient to validate the target exposure of anakinra across the full continuum spanning PK, PD, clinical outcomes, and safety, and this review highlights substantial gaps in the clinical PK/PD knowledge on anakinra, and model robustness.

Jia Li, Megan Clark, D. Metz et al. · Clinical Pharmacokinetics · 1 citation